Takeaway

• The United States Food and Drug Administration (FDA) has approved lisocabtagene maraleucel, also known as liso-cel, for the second-line treatment of adults with relapsed or refractory large B-cell lymphoma (r/r LBCL), including diffuse LBCL not otherwise specified, high-grade B-cell lymphoma, primary mediastinal LBCL, and follicular lymphoma grade 3B.

Key...